Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir. Issue 7 (1st June 2016)

• Record Type: Journal Article
• Authors: Safadi, Rifaat; Noviello, Stephanie; Boparai, Navdeep; McPhee, Fiona
• Is Part Of: Clinical case reports. Volume 4:Issue 7(2016)
• Page Start: 653
• Page End: 656
• Publication Date: 2016-06-01
• Subjects: Asunaprevir -- daclatasvir -- HCV -- retreatment; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.581
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: There is currently minimal clinical experience regarding retreatment options for patients failing direct‐acting antiviral combination regimens. Here, we report the outcomes of a HCV genotype 1b‐infected patient with virologic failure following treatment with daclatasvir and asunaprevir, who was successfully retreated with sofosbuvir plus simeprevir. Abstract : Viral decline during initial treatment (daclatasvir plus asunaprevir) and retreatment (sofosbuvir plus simeprevir). a Initial treatment with daclatasvir and asunaprevir for 24 weeks; b Retreatment with sofosbuvir and simeprevir for 12 weeks. BL, baseline; EOT, end of treatment; FU, follow‐up week; HCV, hepatitis C virus.